| Literature DB >> 31245791 |
Ana Cristina Schmidt de Oliveira-Netto1, Luis G Morello2,3, Libera M Dalla-Costa4,5, Ricardo R Petterle6, Rafael M Fontana7, Danieli Conte3, Luciane A Pereira3, Sonia M Raboni1,7.
Abstract
PURPOSE: Sepsis is a condition with high mortality rates and its diagnosis remains a challenge. We assessed epidemiological, clinical data, multiple biomarker profiles, and blood culture with respect to sepsis diagnosis and predictors of outcome.Entities:
Keywords: C-reactive protein; biomarkers; epidemiology; procalcitonin; sepsis
Year: 2019 PMID: 31245791 PMCID: PMC6582287 DOI: 10.1177/2632010X19847673
Source DB: PubMed Journal: Clin Pathol ISSN: 2632-010X
Demographic, clinical, and laboratory findings in study groups (n = 183).
| Group 1 | Group 2 | Group 3 | Univariate analysis | |
|---|---|---|---|---|
| Sepsis, N = 78 (%) | Septic shock, N = 50 (%) | Non-sepsis, N = 55 (%) | ||
| Sex | ||||
| Male | 44 (56) | 29 (58) | 33(60) | NS |
| Age (years), median (IQR) | 60 (36–69) | 53.5 (43.7–70) | 49 (37–69) | NS |
| Length of hospital, in days, median (IQR) | 23 (13–33.5) | 16 (7.7–43.2) | 20 (10–37) | NS |
| Charlson probability of 10–year survival[ | ||||
| 99% to 90% | 47 (60) | 29 (58) | 29 (52) | NS |
| 77% to 53% | 17 (22) | 12 (24) | 13 (24) | |
| 21% | 14 (18) | 9 (18) | 13 (24) | |
| Leukogram (cells/μL), median (IQR) | 10 020 (6990–12 470) | 9760 (6305–18 560) | 8960 (5703–13 278) | NS |
| Leukogram (cells/μL) | ||||
| <3800 | 8 (11) | 8 (16) | 6 (11) | NS |
| 3801 to 10 999 | 35 (49) | 20 (41) | 28 (52) | |
| >11 000 | 28 (40) | 21 (43) | 20 (37) | |
| Platelets (×103/μL), median (IQR) | 204 (102–301) | 165 (62–264) | 200 (109.5–296) | NS |
| Case fatality | 24 (31) | 34 (68) | 14 (25) |
|
| Serum albumin (g/dL), median (IQR) | 2.6 (2.3–3.2) | 2.2 (1.8–2.7) | 2.8 (2.6–3.3) |
|
| Serum CRP (mg/L), median (IQR) | 10.7 (4.9–16.2) | 16.3 (7.2–21.7) | 8.6 (4–14) |
|
| Serum PCT (ng/mL), median (IQR) | 0.4 (0.1–2.1) | 4.28 (0.79–32.7) | 0.36 (0.1–0.9) |
|
| Serum PCT (ng/mL) | ||||
| ⩽0.5 | 40 (52) | 8 (16.5) | 31 (57) |
|
| 0.51 to 1.9 | 15 (19) | 14 (28.5) | 14 (26) | |
| ⩾2 | 22 (29) | 27 (55) | 9 (17) | |
| APACHE II score, median (IQR) | 14 (10–19) | 22 (18–27) | 13 (8–21) |
|
| SOFA 1st day, median (IQR) | 3 (1–5) | 8.5 (7–11) | 4 (1–6) |
|
| Acquired infection | ||||
| Hospital | 45 (58) | 29 (58) | — | NS |
| Community | 33 (42) | 21(42) | ||
| Blood culture | ||||
| Positive | 22 (28) | 21 (42) | — |
|
| Negative | 56 (72) | 29 (58) | ||
Abbreviations: APACHE, Acute Physiology and Chronic Health Evaluation; CRP, C-reactive protein; IQR, interquartile range; NS, non significant; PCT, procalcitonin; SOFA, Sepsis-related Organ Failure Assessment.
Significant values are in bold.
A total of 40 patients do not have any comorbidities.
Significant differences only for Group 2.
Figure 1.Infection sources of community- and hospital-acquired infections.
Figure 2.Pathogens identified in blood cultures.
*SCoN indicates coagulase-negative Staphylococcus sp.; Staphylococcus haemolyticus; MSSA, methicillin-susceptible Staphylococcus aureus; MRSA, methicillin-resistant Staphylococcus aureus; ESBL, extended spectrum beta-lactamase.
CESP group:[15] Enterobacter cloacae (n = 1), Serratia marcescens (n = 2), and Citrobacter koseri (n = 1).
Demographic, clinical, and biomarker findings in predicting outcome in studied patients (n = 183 patients).
| Variable | Discharge, n = 111 (%) | Death, n = 72 (%) | Unadjusted analysis | Adjusted analysis | ||
|---|---|---|---|---|---|---|
| OR | 95% CI | |||||
| Age, years, median (IQR) | 48 (31–66) | 62.5 (52–72.7) |
|
| 1.03 | 1.01 to 1.05 |
| Charlson comorbidity index* | ||||||
| 99% to 90% | 68 (61) | 37 (51) | .174 | — | — | — |
| 77% to 53% | 26 (24) | 16 (22) | ||||
| 21% | 17 (15) | 19 (27) | ||||
| APACHE II score, median (IQR) | 13 (8–19) | 21 (15–25) |
|
| 1.07 | 1.0 to 1.15 |
| SOFA 1st day, median (IQR) | 3 (1–5) | 7 (3–10) |
|
| 1.15 | 1.01 to 1.31 |
| Serum albumin (g/dL), median (IQR) | 2.8 (2.4–3.3) | 2.4 (1.9–2.8) |
|
| 0.5 | 0.28 to 0.86 |
| Serum CRP (mg/L), median (IQR) | 9.9 (4.3–15.9) | 28.1 (19–37.7) | .068 | — | — | — |
| Serum PCT (ng/mL), median (IQR) | 0.4 (0.1–2) | 1.4 (0.4 (7.2) |
| .623 | — | — |
| Serum PCT (ng/mL) | ||||||
| ⩽0.5 | 59 (54) | 20 (28) |
| 0.341 | ||
| 0.51 to 1.9 | 22 (20) | 21 (30) | ||||
| ⩾2 | 28 (26) | 30 (42) | ||||
| Blood culture | ||||||
| Positive | 20 (18) | 23 (32) |
| 0.244 | ||
| Negative | 91 (82) | 49 (68) | ||||
| Platelets (×103/μL), median (IQR) | 205 (109–304) | 175 (65–244) |
| .345 | ||
| Final classification | ||||||
| Sepsis | 54 (49) | 24 (33) |
| 0.118 | ||
| Septic shock | 16 (14) | 34 (47) | ||||
| Non-sepsis | 41 (37) | 14 (20) | ||||
Abbreviation: APACHE, Acute Physiology and Chronic Health Evaluation; CI, confidence interval; CRP, C-reactive protein; IQR, interquartile range; OR: odds ratio; PCT, procalcitonin; SOFA, Sepsis-related Organ Failure Assessment.
Significant values are in bold.
Figure 3.Receiver operating characteristic (ROC) curves for procalcitonin, CRP, and albumin to predict fatality.